Estudos

http://aformulabr.com.br/qrcode/alfagpcafv01.pdf
 ALFA GPC
Precursor da acetilcolina de maior biodisponibilidade sob
a forma de fosfolipídio para hipertrofia muscular

DESCRIÇÃO
A α-glicerilfosforilcolina (Alfa GPC) é um fosfolipídio derivado da fosfatidilcolina (percursor da acetilcolina) que possui
elevada biodisponibilidade, quando comparada a outras formas de colina, ressaltando sua capacidade em atravessar
a barreira hemato-encefálica.

MECANISMO DE AÇÃO
O Alfa GPC atua com maior disponibilidade de acetilcolina no organismo fazendo com que a resposta do hormônio
de crescimento (GH) aos exercícios físicos se torne mais significativa, as células dos tecidos musculares esqueléticos
sejam estimuladas e sua ação sob o SNC, a memória e aprendizados se tornem otimizados (entre eles melhora da
função cognitiva, além do controle da perda de memória e demência).

INDICAÇÕES

 Funções cognitivas;
 Coadjuvante no tratamento de Alzheimer (principalmente associado com Huperzine A);
 Aumento no desempenho muscular.

DOSE USUAL
Recomendação oral de 250mg a 300mg de Alfa GPC, ao dia, na suplementação. Para disfunções cognitivas
severas, recomendação oral de 1.000mg a 1.500mg ao dia.

SUGESTÕES DE FÓRMULAS

Alfa GPC............................................................. 50mg Alfa GPC........................................................... 100mg

Ubiquinol.............................................................. 25mg Vimpocetine........................................................... 5mg
Turkesterone. 2% (Ajuga turkestanica extract).......... 250mg Huperzine A..................................................... 100mcg
Caseína micelar................................................. 250mg Metilcobalamina (MB 12)................................ 100mcg

Modo de uso: 1 dose antes do treino.

Indicação: Aumento do desempenho e ganho de Modo de uso: 01 dose ao dia.
massa muscular. Indicação: Coadjuvante no tratamento do Alzheimer.

PRINCIPAIS REFERÊNCIAS

Vida Saudável. Conheça tudo sobre o Alfa-GPC. Disponível em:< http://saudavelvida.com/conheca-tudo-sobre-o-alfa-gpc/>. Acesso em: 26 de
Maio de 2015, às 10:44.

ZIEGENFUSS T.; LANDIS J.; HOFHEINS J. Acute supplementation with alpha-glycerylphosphorylcholine augments growth hormone response to,
and peak force production during, resistance exercise. Journal of the International Society of Sports Nutrition. V.5, nº1, p.15. Disponível em:<
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313098/>. Acesso em: 26 de Abril de 2016, às 08:19.
 ALGA GPC
ESTUDOS CLÍNICOS

Alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter

clinical trial

The clinical efficacy and the tolerability of alpha-glycerophosphocholine (alpha-GPC), a drug able to provide high
levels of choline for the nervous cells of the brain and to protect their cell walls, have been tested in a clinical open
multicenter trial on 2044 patients suffering from recent stroke or transient ischemic attacks. alpha-GPC was
administered after the attack at the daily dose of 1000 mg im for 28 days and orally at the dose of 400 mg tid during
the following 5 months after the first phase. The evaluation of the efficacy on the psychic recovery was done by the
Mathew Scale (MS) during the period of im drug administration, and using the Mini Mental State Test (MMST), the
Crichton Rating Scale (CRS), and the Global Deterioration Scale (GDS) during the following period of oral
administration. The MS mean increased 15.9 points in 28 days in a statistically significant way (p < 0.001) from 58.7 to
74.6. At the end of the 5 month oral administration, the CRS mean significantly decreased 4.3 points, from 20.2 to
15.9 (p < 0.001); the MMST mean significantly increased (p < 0.001) from 21 to 24.3 at the end of the trial, reaching
the "normality" score at the 3rd month assessment. The GDS score at the end of the trial corresponded to "no
cognitive decline" or "forgetfulness" in 71% of the patients. Adverse events were complained of by 44 patients
(2.14%); in 14 (0.7%) the investigator preferred to discontinue therapy. The most frequent complaints were heartburn
(0.7%), nausea-vomit (0.5%), insomnia-excitation (0.4%), and headache (0.2%). The trial confirms the therapeutic role
of alpha-GPC on the cognitive recovery of patients with acute stroke or TIA, and the low percentage of adverse events
confirms its excellent tolerability.

Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine
precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial

BACKGROUND: Parallel with the development of hypotheses regarding cholinergic involvement in geriatric memory
dysfunction, the first attempts to treat patients with Alzheimer's disease (AD) involved the cholinergic-precursor
loading approach. Despite encouraging early results, well-controlled clinical trials did not confirm a clinical utility of
cholinergic precursors such as choline and lecithin (phosphatidylcholine) in AD. RESULTS: A total of 261 patients
(132 in the CA group, 129 in the placebo group) were enrolled in the study. The mean (SD) age in the CA group was
72.2(7.5) years (range, 60-80 years), and in the placebo group it was 71.7 (7.4) years(range, 60-80 years). The CA
group comprised 105 women and 27 men; the placebo group, 94 women and 35 men. The mean decrease in ADAS-
Cog score in patients treated with CA was 2.42 points after 90 days of treatment and 3.20 points at the end of the
study (day 180) (P < 0.001 vs baseline for both), whereas in patients receiving placebo the mean increase in ADAS-
Cog score was 0.36 point <1 after 90 days of treatment and 2.90 points after 180 days of treatment(P < 0.001 vs
baseline). In the CA group, all other assessed parameters (MMSE,GDS, ADAS-Behav, ADAS-Total, and CGI)
consistently improved after 90 and 180 days versus baseline, whereas in the placebo group they remained unchanged
or worsened. Statistically significant differences were observed between treatments after 90 and 180 days in ADAS-
Cog, MMSE, GDS, ADAS-Total, and CGI scores and after 180 days of treatment in ADAS-Behav and GIS scores.
CONCLUSION: The results of this study suggest the clinical usefulness and tolerability of CA in the treatment of the
cognitive symptoms of dementia disorders of the Alzheimer type.

Behavioral effects of L-alpha-glycerylphosphorylcholine: influence on cognitive mechanisms in the rat

The phosphorylcholine precursor, L-alpha-glycerylphosphorylcholine (alpha-GPC), was injected at the dose of 100
mg/kg/day for 20 days to aged male rats of the Sprague-Dawley strain, 24 months old, showing a deficit of learning
and memory capacity. The drug was also administered to rats with amnesia induced pharmacologically with bilateral
injections of kainic acid into the nucleus basalis magnocellularis (NBM). Learning and memory capacity of the animals,
studied with tests of active and passive avoidance behavior, was improved after treatment with alpha-GPC in all
experimental groups. These results indicate that this drug affects cognitive mechanisms in the rat through an
involvement of central neurotransmission.
Acute supplementation with alpha-glycerylphosphorylcholine augments growth hormone response to, and
peak force production during, resistance exercise

Background Many of the positive adaptations resulting from resistance exercise training (i.e., increased muscle mass
and strength, decreased fat mass) are thought to be mediated, in part, by exercise-induced increases in growth
hormone (GH). All trials were performed after an overnight fast, a 48-hour abstention from intense exercise, and
during the same time of day to minimize diurnal variation. Serum samples were obtained prior to exercise and again 0,
5, 15, 30, 60, 90 and 120 minutes post-exercise. Hormone concentrations were analyzed in duplicate by Quest
Diagnostics® via immunoassay. Statistical evaluation of the data was accomplished using dependent ttests (peak
force, peak power, rate of force development) and repeated measures ANOVA (GH, RMR, RER). Differences were
considered "significant" at P ≤ 0.05. Results Compared to baseline (pre) values, peak GH increased 44-fold during A-
GPC (from 0.19 ± 0.06 to 8.4 ± 2.1 ng/ mL) vs. 2.6-fold during placebo (from 1.9 ± 0.8 to 5.0 ± 4.8 ng/mL, P < 0.03)
(Figure 1). Peak bench press force was 14% greater in A-GPC (933 ± 89 N) vs. placebo (818 ± 77 N, P < 0.02).
Trends toward higher peak bench press power (P < 0.13) and lower post-exercise RER (P < 0.12) were noted in the
A-GPC trial. Conclusion These data indicate that a single 600 mg dose of A-GPC (as AlphaSize™), when
administered 90 minutes prior to resistance exercise, increases post-exercise serum GH and peak bench press force.
In contrast, A-GPC had no statistically significant effect on peak power, rate of force development, RMR, or
cardiovascular hemodynamics (i.e., heart rate and blood pressure). Future work should examine how resistance
exercise + A-GPC affect the GH-IGF axis and their associated family of binding proteins.

REFERÊNCIAS
SANGIORGI B.G.; BARBAGALLO M.; GIORDANO M.; MELI M.; PANZARASA R. alpha-Glycerophosphocholine in the mental recovery of
cerebral ischemic attacks. An Italian multicenter clinical trial. Ann N Y Acad Sci. V.30; nº717, p.253-69. Jun; 1994. Disponível em:
http://www.ncbi.nlm.nih.gov/pubmed/8030842>. Acesso em: 26 de Maio de 2015, às 09:14.

MORENO J.M.; Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline
alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther. V.25, nº1, p.178-93. Jan; 2003. Disponível em:<
http://www.ncbi.nlm.nih.gov/pubmed/12637119>. Acesso em: 26 de Maio de 2015, às 09:42.

DRAGO F.; MAUCERI F.; NARDO L.; VALERIO C.; LAURIA N.; RAMPELLO L.; GUIDI G. Behavioral effects of L-alpha-
glycerylphosphorylcholine: influence on cognitive mechanisms in the rat. Pharmacol Biochem Behav. V.41, nº2, p.445-8. Feb; 1992. Disponível
em:< http://www.ncbi.nlm.nih.gov/pubmed/1574535>. Acesso em: 26 de Maio de 2015, às 09:47.

ZIEGENFUSS T.; LANDIS J.; HOFHEINS J. Acute supplementation with alpha-glycerylphosphorylcholine augments growth hormone response to,
and peak force production during, resistance exercise. Journal of the International Society of Sports Nutrition. V.5, nº1, p.15. Disponível em:<
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313098/>. Acesso em: 26 de Abril de 2016, às 08:19.